Barclays upgraded Novozymes to Overweight from Equal Weight with a price target of DKK 364, up from DKK 330. The company has exhibited strong underlying momentum and its valuations versus the ingredients peer group is below long-term average, providing an attractive entry point, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVZMY:
